A predictive model for the detection of tumor lysis syndrome during AML induction therapy

Anthony R. Mato, Brett E. Riccio, Li Qin, Daniel F. Heitjan, Martin Carroll, Alison Loren, David L. Porter, Alexander Perl, Edward Stadtmauer, Donald Tsai, Alan Gewirtz, Selina M. Luger

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Tumor lysis syndrome (TLS) is defined by metabolic derangements occurring in the setting of rapid tumor destruction. In acute myelogenous leukemia (AML), TLS frequency, risk stratification, monitoring, and management strategies are based largely on case series and data from other malignancies. A single-center, retrospective cohort study was conducted to estimate TLS incidence and identify TLS predictive factors in a patient population undergoing myeloid leukemia induction chemotherapy. This study included 194 patients, aged 18-86 years, with AML or advanced myelodysplastic syndrome undergoing primary myeloid leukemia induction chemotherapy. Nineteen patients (9.8%) developed TLS. In univariate analysis, elevated pre-chemotherapy values for uric acid (P < 0.0001), creatinine (P = 0.0025), lactate dehydrogenase (LDH) (P = 0.0001), white blood cell (P = 0.0058), gender (P = 0.0064) and chronic myelomonocytic leukemia history (P = 0.0292) were significant predictors. In multivariate analysis, LDH (P=0.0042), uric acid (P < 0.0001) and gender (P = 0.0073) remained significant TLS predictors. A predictive model was then designed using a scoring system based on these factors. This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population.

Original languageEnglish (US)
Pages (from-to)877-883
Number of pages7
JournalLeukemia and Lymphoma
Volume47
Issue number5
DOIs
StatePublished - May 1 2006

Fingerprint

Tumor Lysis Syndrome
Acute Myeloid Leukemia
Induction Chemotherapy
Myeloid Leukemia
Uric Acid
L-Lactate Dehydrogenase
Therapeutics
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Population
Creatinine
Neoplasms
Leukocytes
Cohort Studies
Multivariate Analysis
Retrospective Studies
Guidelines
Drug Therapy
Incidence

Keywords

  • Acute myeloid leukemia
  • Acute renal failure
  • Hyperuricemia
  • Tumor lysis syndrome
  • Urate nephropathy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A predictive model for the detection of tumor lysis syndrome during AML induction therapy. / Mato, Anthony R.; Riccio, Brett E.; Qin, Li; Heitjan, Daniel F.; Carroll, Martin; Loren, Alison; Porter, David L.; Perl, Alexander; Stadtmauer, Edward; Tsai, Donald; Gewirtz, Alan; Luger, Selina M.

In: Leukemia and Lymphoma, Vol. 47, No. 5, 01.05.2006, p. 877-883.

Research output: Contribution to journalArticle

Mato, AR, Riccio, BE, Qin, L, Heitjan, DF, Carroll, M, Loren, A, Porter, DL, Perl, A, Stadtmauer, E, Tsai, D, Gewirtz, A & Luger, SM 2006, 'A predictive model for the detection of tumor lysis syndrome during AML induction therapy', Leukemia and Lymphoma, vol. 47, no. 5, pp. 877-883. https://doi.org/10.1080/10428190500404662
Mato, Anthony R. ; Riccio, Brett E. ; Qin, Li ; Heitjan, Daniel F. ; Carroll, Martin ; Loren, Alison ; Porter, David L. ; Perl, Alexander ; Stadtmauer, Edward ; Tsai, Donald ; Gewirtz, Alan ; Luger, Selina M. / A predictive model for the detection of tumor lysis syndrome during AML induction therapy. In: Leukemia and Lymphoma. 2006 ; Vol. 47, No. 5. pp. 877-883.
@article{92c8e3c8f5d947368d19ae38b552c767,
title = "A predictive model for the detection of tumor lysis syndrome during AML induction therapy",
abstract = "Tumor lysis syndrome (TLS) is defined by metabolic derangements occurring in the setting of rapid tumor destruction. In acute myelogenous leukemia (AML), TLS frequency, risk stratification, monitoring, and management strategies are based largely on case series and data from other malignancies. A single-center, retrospective cohort study was conducted to estimate TLS incidence and identify TLS predictive factors in a patient population undergoing myeloid leukemia induction chemotherapy. This study included 194 patients, aged 18-86 years, with AML or advanced myelodysplastic syndrome undergoing primary myeloid leukemia induction chemotherapy. Nineteen patients (9.8{\%}) developed TLS. In univariate analysis, elevated pre-chemotherapy values for uric acid (P < 0.0001), creatinine (P = 0.0025), lactate dehydrogenase (LDH) (P = 0.0001), white blood cell (P = 0.0058), gender (P = 0.0064) and chronic myelomonocytic leukemia history (P = 0.0292) were significant predictors. In multivariate analysis, LDH (P=0.0042), uric acid (P < 0.0001) and gender (P = 0.0073) remained significant TLS predictors. A predictive model was then designed using a scoring system based on these factors. This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population.",
keywords = "Acute myeloid leukemia, Acute renal failure, Hyperuricemia, Tumor lysis syndrome, Urate nephropathy",
author = "Mato, {Anthony R.} and Riccio, {Brett E.} and Li Qin and Heitjan, {Daniel F.} and Martin Carroll and Alison Loren and Porter, {David L.} and Alexander Perl and Edward Stadtmauer and Donald Tsai and Alan Gewirtz and Luger, {Selina M.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1080/10428190500404662",
language = "English (US)",
volume = "47",
pages = "877--883",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - A predictive model for the detection of tumor lysis syndrome during AML induction therapy

AU - Mato, Anthony R.

AU - Riccio, Brett E.

AU - Qin, Li

AU - Heitjan, Daniel F.

AU - Carroll, Martin

AU - Loren, Alison

AU - Porter, David L.

AU - Perl, Alexander

AU - Stadtmauer, Edward

AU - Tsai, Donald

AU - Gewirtz, Alan

AU - Luger, Selina M.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Tumor lysis syndrome (TLS) is defined by metabolic derangements occurring in the setting of rapid tumor destruction. In acute myelogenous leukemia (AML), TLS frequency, risk stratification, monitoring, and management strategies are based largely on case series and data from other malignancies. A single-center, retrospective cohort study was conducted to estimate TLS incidence and identify TLS predictive factors in a patient population undergoing myeloid leukemia induction chemotherapy. This study included 194 patients, aged 18-86 years, with AML or advanced myelodysplastic syndrome undergoing primary myeloid leukemia induction chemotherapy. Nineteen patients (9.8%) developed TLS. In univariate analysis, elevated pre-chemotherapy values for uric acid (P < 0.0001), creatinine (P = 0.0025), lactate dehydrogenase (LDH) (P = 0.0001), white blood cell (P = 0.0058), gender (P = 0.0064) and chronic myelomonocytic leukemia history (P = 0.0292) were significant predictors. In multivariate analysis, LDH (P=0.0042), uric acid (P < 0.0001) and gender (P = 0.0073) remained significant TLS predictors. A predictive model was then designed using a scoring system based on these factors. This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population.

AB - Tumor lysis syndrome (TLS) is defined by metabolic derangements occurring in the setting of rapid tumor destruction. In acute myelogenous leukemia (AML), TLS frequency, risk stratification, monitoring, and management strategies are based largely on case series and data from other malignancies. A single-center, retrospective cohort study was conducted to estimate TLS incidence and identify TLS predictive factors in a patient population undergoing myeloid leukemia induction chemotherapy. This study included 194 patients, aged 18-86 years, with AML or advanced myelodysplastic syndrome undergoing primary myeloid leukemia induction chemotherapy. Nineteen patients (9.8%) developed TLS. In univariate analysis, elevated pre-chemotherapy values for uric acid (P < 0.0001), creatinine (P = 0.0025), lactate dehydrogenase (LDH) (P = 0.0001), white blood cell (P = 0.0058), gender (P = 0.0064) and chronic myelomonocytic leukemia history (P = 0.0292) were significant predictors. In multivariate analysis, LDH (P=0.0042), uric acid (P < 0.0001) and gender (P = 0.0073) remained significant TLS predictors. A predictive model was then designed using a scoring system based on these factors. This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population.

KW - Acute myeloid leukemia

KW - Acute renal failure

KW - Hyperuricemia

KW - Tumor lysis syndrome

KW - Urate nephropathy

UR - http://www.scopus.com/inward/record.url?scp=33744924241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744924241&partnerID=8YFLogxK

U2 - 10.1080/10428190500404662

DO - 10.1080/10428190500404662

M3 - Article

C2 - 16753873

AN - SCOPUS:33744924241

VL - 47

SP - 877

EP - 883

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -